Indian Pharmacopoeia Commission: IP 2026, Drug Standards and Pharmacovigilance
Category: Science & Technology → Pharmaceuticals → Health Regulation
Why in News?
The Indian Pharmacopoeia Commission (IPC) has been prominent in 2026 following the release of Indian Pharmacopoeia 2026 and new reference standards for pharmaceutical impurities.
About IPC
- Autonomous institution under the Ministry of Health & Family Welfare.
- Responsible for developing and publishing the Indian Pharmacopoeia (IP).
- Indian Pharmacopoeia establishes official standards for medicines marketed/manufactured in India.
Indian Pharmacopoeia 2026
- 10th edition
- Released → 2 January 2026
- Added → 121 new monographs
- Total → approximately 3,340 monographs.
Other Functions
IPC is associated with:
- Pharmacopoeial standards
- Reference substances
- Impurity standards
- Pharmacovigilance
- National Formulary of India
2026 Nitrosamine Development
IPC launched seven nitrosamine impurity reference standards, including NDMA and NDEA, to strengthen detection and quality control of pharmaceutical impurities.
Key Pointers
- IPC → Ministry of Health & Family Welfare
- Headquarters → Ghaziabad
- Main publication → Indian Pharmacopoeia
- IP 2026 → 10th edition
- New monographs → 121
- Related programme → Pharmacovigilance Programme of India
Share this article